Kazia Therapeutics has dosed the first patient in a Phase 2 trial (PNOC035) testing paxalisib combined with gemcitabine for children and young adults with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive pediatric brain cancer with no approved treatments. Preclinical studies showed this drug combo significantly extended survival in models, supporting this clinical evaluation. The trial is led by the Pediatric Neuro-Oncology Consortium and aims to address a critical unmet need in pediatric brain cancer therapy. If successful, paxalisib could gain FDA approval and a priority review voucher, advancing treatment options for this devastating disease.
InMode Ltd. has introduced Morpheus8 Cool, an advanced version of its popular Morpheus8 RF microneedling technology, now available on the new Morpheus8MAX platform. This upgrade features Cool Comfort Technology for improved patient comfort by cooling...
Decade Resources Ltd. is expanding its exploration at the Bonaparte copper-gold property in British Columbia by adding 1,000 meters to its drill program, increasing land holdings by 1,400 hectares, and opening a new exploration area 5 km east of curr...
Warren Buffett's Berkshire Hathaway holds about 50% of its disclosed US stock portfolio in just three companies: Apple, American Express, and Coca-Cola. These consumer-focused giants have strong brand power, consistent cash flow, and long-term holdin...
Ituran Location and Control Ltd. secured a four-year contract worth over $7 million with the Israeli Ministry of Transport to provide a SaaS solution for live traffic monitoring across Israel's main roads. The service uses Ituran's Big Data platform,...
Americore Resources Corp. reported confirmatory sampling results from the Trinity Silver Project in Nevada, showing silver grades equal to or higher than historical assays, including up to 509 g/t silver. The sampling also revealed polymetallic miner...
